NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

市场调查报告书

骨髓增生性肿瘤治疗药物市场市场规模,份额,前景,机会分析:2020-2027

Myeloproliferative Neoplasm Drugs Market, by Drug Class, by Indication (Ph+ Chronic myelogenous leukemia, Ph- Myeloproliferative Neoplasms, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品编码 995629
出版日期 内容资讯 英文 222 Pages
商品交期: 2-3个工作天内
价格
骨髓增生性肿瘤治疗药物市场市场规模,份额,前景,机会分析:2020-2027 Myeloproliferative Neoplasm Drugs Market, by Drug Class, by Indication (Ph+ Chronic myelogenous leukemia, Ph- Myeloproliferative Neoplasms, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2021年02月17日内容资讯: 英文 222 Pages
简介

骨髓增生性肿瘤(MPN)是一种罕见的血液癌,可导致个体骨髓中过多的红细胞,白细胞或血小板生成。领先的公司正在关注诸如并购等战略,并有望推动全球骨髓增生性肿瘤药物市场的增长。

本报告对全球骨髓增生性肿瘤治疗药物市场进行了研究和分析,并系统地提供了市场概况,市场规模和预测,按细分市场的分析,按地区进行的市场分析,竞争情况等。

目录

第1章调查目标和前提条件

第2章市场范围

第3章市场动态/法规/趋势分析

  • 促进因素
  • 抑制器
  • 市场机会
  • 影响分析
  • 主要发展
  • 产品发布/批准
  • 并购,联盟
  • 管道分析
  • 监管情况
  • PEST分析
  • 流行病学
  • 市场份额分析

第4章,全球骨髓增生性肿瘤治疗市场,COVID-19大流行的影响

  • 供方和需方分析
  • COVID-19对整个医疗保健行业的影响
  • COVID-19对临床试验和药物开发的影响
  • COVID-19对癌症治疗的作用

第5章:全球骨髓增生性肿瘤治疗市场:按药物分类

  • 简介
  • 市场份额分析
  • 同比增长率分析
  • 脱甲基剂
  • 酪氨酸激□抑制剂
  • 多激□抑制剂
  • JAK2抑制剂
  • 其他

第6章:全球骨髓增生性肿瘤治疗市场:适应症

  • 简介
  • 市场份额分析
  • 同比增长率分析
  • 细分趋势
    • Ph +慢性粒细胞性白血病(CML)
    • 骨髓增生性肿瘤(MPN)
    • 骨髓纤维化(MF)
    • 真性红细胞增多症(PV)
    • 原发性血小板增多症(ET)

第7章:全球骨髓增生性肿瘤治疗市场:通过分销渠道

  • 简介
  • 市场份额分析
  • 同比增长率分析
  • 细分趋势
    • 医院药房
    • 零售药房
    • 在线药房

第8章全球骨髓增生性肿瘤治疗市场:按地区

  • 简介
  • 市场份额分析:按国家
  • 同比增长率分析:按国家
  • 北美
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第9章竞争情况

  • 公司简介
  • Novartis International AG
  • 临床试验阶段产品组合
  • PharmaEssentia Corporation
  • 临床试验阶段产品组合
  • Bristol - Myers Squibb
  • 临床试验阶段产品组合
  • Pfizer, Inc.
  • 临床试验阶段产品组合
  • Takeda Pharmaceutical Company Limited
  • 临床试验阶段产品组合
  • Incyte
  • 临床试验阶段产品组合
  • Johnson & Johnson
  • 临床试验阶段产品组合
  • Teva Pharmaceutical Industries Ltd.
  • 临床试验阶段产品组合
  • F. Hoffmann-La Roche AG
  • 临床试验阶段产品组合
  • Gamida Cell
  • 临床试验阶段产品组合
  • Sierra Oncology, Inc.
  • 临床试验阶段产品组合
  • CTI BioPharma Corp.
  • 临床试验阶段产品组合
  • Imago BioSciences
  • 临床试验阶段产品组合
  • AbbVie Inc.
  • 临床试验阶段产品组合
  • Constellation Pharmaceuticals
  • 临床试验阶段产品组合
目录

Title:
Myeloproliferative Neoplasm Drugs Market, by Drug Class (Demethylation Agents, Tyrosine kinase Inhibitor, Multikinase Inhibitors, JAK2 Inhibitor, and Others), by Indication (Ph+ Chronic myelogenous leukemia (CML), Ph- Myeloproliferative Neoplasms (MPNs) (Myelofibrosis (MF), Polycythemia Vera (PV), Essential Thrombocythemia (ET)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Myeloproliferative neoplasms (MPNs) are a type of rare blood cancers, which leads to production of excess red blood cells, white blood cells, or platelets in the bone marrow of individuals. Myelo refers to bone marrow and spinal cord of the individual and proliferative describes the rapid growth of blood cells, whereas neoplasm describes the abnormal and uncontrolled growth of cells in patients. The overproduction of blood cells is often associated with a somatic mutation, for example, the over production of JAK2 (Janus kinase 2) leads to chronic myeloproliferative disorders. The various drug classes indicated for the treatment of myeloproliferative neoplasm are demethylation agents, tyrosine kinase inhibitor, multikinase inhibitors, JAK2 inhibitor, and others.

Market Dynamics

Key companies are focusing on strategies such as mergers and acquisitions, which is expected to drive the global myeloproliferative neoplasm drugs market growth. For instance, in January 2019, Takeda Pharmaceutical Company Limited acquired Shire Inc (a biopharmaceutical company in U.K.),to expand its geographical presence in the market and enhance its product portfolio through research and development activities.

Moreover, key players are focusing on product launches and product approvals to strengthen their presence in the global myeloproliferative neoplasm drugs market. For instance, in November 2018, Pfizer Inc. received the U.S. Food and Drug Administration approval for Daurismo for use in adults with acute myeloid leukemia (AML) in 75 years or older patients.

Furthermore, in December 2017, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for a supplemental New Drug Application (sNDA) to expand the indication of BOSULIF (bosutinib) to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).

Key features of the study:

  • This report provides in-depth analysis of the global myeloproliferative neoplasm drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020-2027)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
  • It profiles leading players in the global myeloproliferative neoplasm drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
  • The global myeloproliferative neoplasm drugs market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global myeloproliferative neoplasm drugs market

Detailed Segmentation:

  • Global Myeloproliferative Neoplasm Drugs Market, By Drug Class:
    • Demethylation Agents
    • Tyrosine kinase Inhibitor
    • Multikinase Inhibitors
    • JAK2 Inhibitor
    • Others
  • Global Myeloproliferative Neoplasm Drugs Market, By Indication:
    • Ph+ Chronic myelogenous leukemia (CML)
    • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
  • Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Myeloproliferative Neoplasm Drugs Market, By Region:
    • North America
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class:
      • Demethylation Agents
      • Tyrosine kinase Inhibitor
      • Multikinase Inhibitors
      • JAK2 Inhibitor
      • Others
      • By Indication:
      • Ph+ Chronic myelogenous leukemia (CML)
      • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Novartis International AG.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bristol - Myers Squibb
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Incyte
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche AG
    • Gamida Cell
    • Sierra Oncology, Inc.
    • CTI BioPharma Corp.
    • Imago BioSciences
    • AbbVie Inc.
    • Constellation Pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

  • Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations
  • Market Purview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)
  • Market Dynamics, Regulations, and Trends Analysis
  • Drivers
  • Restraints
  • Opportunities
  • Impact Analysis
  • Key Developments
  • Product Launch/ Approvals
  • Mergers, Acquisition & Collaboration
  • Pipeline Analysis
  • Regulatory Scenario
  • PEST Analysis
  • Epidemiology
  • Market Share Analysis
  • Global Myeloproliferative Neoplasm Drugs Market, Impact of COVID-19 Pandemic
  • Supply Side and Demand Side Analysis
  • COVID-19 Impact on Overall Healthcare Sector
  • COVID-19 Impact on Clinical Trials and Drug Development
  • COVID-19 Impact on Cancer Treatment
  • Global Myeloproliferative Neoplasm Drugs Market, By Drug Class, 2016-2027 (US$ Mn)
  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
    • Segment Trends
  • Demethylation Agents
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • Tyrosine kinase Inhibitor
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • Multikinase Inhibitors
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • JAK2 Inhibitor
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • Others
    • Introduction
    • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
  • Global Myeloproliferative Neoplasm Drugs Market, By Indication, 2016 - 2027, (US$ Mn)
  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017- 2027
  • Segment Trends
    • Ph+ Chronic myelogenous leukemia (CML)
  • Introduction
  • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
    • Ph- Myeloproliferative Neoplasms (MPNs)
  • Introduction
  • Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
    • Myelofibrosis (MF)
    • Polycythemia Vera (PV)
    • Essential thrombocythemia (ET)
  • Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel, 2016-2027 (US$ Mn)
  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017- 2027
  • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2027, (US$ Mn)
  • Global Myeloproliferative Neoplasm Drugs Market, By Region, 2016-2027 (US$ Mn)
  • Introduction
  • Market Share Analysis, By Country, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, For Countries, 2017-2027
  • North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2027 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Indication, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2020-2027 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa
  • Competitive Landscape
  • Company Profiles
  • Novartis International AG
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • PharmaEssentia Corporation
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Bristol - Myers Squibb
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Pfizer, Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Takeda Pharmaceutical Company Limited
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Incyte
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Johnson & Johnson
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • F. Hoffmann-La Roche AG
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Gamida Cell
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Sierra Oncology, Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • CTI BioPharma Corp.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Imago BioSciences
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • AbbVie Inc.
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Constellation Pharmaceuticals
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies